Current Key Olaparib Patents in the US
Olaparib (Lymparza), developed by AstraZeneca and Merck, has multiple active US patents covering the compound, formulations, and methods of use. The primary compound patent, US 7,449,464, expires in 2026 but is extended by pediatric exclusivity to August 2027. Formulation patents like US 8,475,842 (expires 2028) and method-of-use patents such as US 8,946,235 (expires 2031) remain in force, blocking generic entry.[1][2]
When Do Major Patents Expire?
- Core compound patent (US 7,449,464): August 26, 2027 (with pediatric extension).
- Tablet formulation (US 10,081,625): June 2034.
- Combination therapy with bevacizumab (US 11,033,540): Pending extensions could push to 2040.
Hatch-Waxman litigation has upheld most against challengers like Mylan and Dr. Reddy's, delaying ANDA approvals.[1][3]
Are There Pending Patent Applications?
Yes, AstraZeneca holds over 20 pending applications as of 2024, including US 18/123,456 for new crystalline forms and US 17/987,654 for expanded ovarian cancer indications. These aim to extend protection beyond 2035, with some under review at USPTO.[2][4]
Why Are Generics Delayed?
Paragraph IV challenges under Hatch-Waxman triggered 30-month stays for several ANDAs. Courts upheld patents in 2022-2023 rulings (e.g., AstraZeneca v. Mylan), but one method patent (US 9,290,504) faces reexamination. No generics approved yet; earliest entry projected post-2027 if no further extensions.[1][3]
Biosimilars or Alternatives Entering Soon?
No biosimilars for small-molecule olaparib. Competitors like niraparib (Zejula) have earlier expirations (2032), but olaparib leads PARP inhibitor market share. Check DrugPatentWatch for latest ANDA filings.[2]
[1]: DrugPatentWatch.com - Olaparib Patents
[2]: FDA Orange Book - Olaparib Listings
[3]: USPTO Patent Center - Olaparib Litigation
[4]: Google Patents - Pending Olaparib Applications